• Ovulation induction:
    • Step-up regimen: Initially SC/IM 37.5-75 units OD *14/7, then may increase by 37.5 units/day no more frequently than every week
      • Max: 225 units/day
    • Step-down regimen: SC/IM 150 units SC/IM OD until dominant follicle development, then decrease to 112.5 units/day *3/7, then decrease to 75 units/day
  • Assisted reproductive technology:
    • With no menotropins: Initially SC 225 units OD *5/7, then may adjust by up to 75-150 units/day no more frequently than every 2 days
      • Max: 225 units/day for start dose, 450 units/day for subsequent doses
    • With menotropins: Initially SC 75 units or 150 units OD *5/7, then may adjust dose by up to 75-150 units/day no more frequently than every 2 days
      • Max: 225 units/day for total urofollitropin and menotropins start dose, 450 units/day for total combined subsequent doses
  • Spermatogenesis induction (Off-label):
    • Initially SC 150 units 3 times /week with hCG 3 times/week
      • Max: 300 units 3 times/week
      • May administer up to 18 months

Injection: 75 units

For ART:

  • Therapy should not exceed 12 days
  • Consider adjusting the dose after 5 days based on ovarian response
  • Do not make additional dosage adjustments more frequently than every 2 days or by >75 -150 IU at each adjustment
  • Continue treatment until adequate follicular development is evident and then administer hCG
  • Do not administer daily doses of urofollitropin or urofollitropin in combination with menotropins that exceed 450 IU

Human FSH; Gonadotropin

It stimulates ovarian follicular growth in women and spermatogenesis in men by stimulating FSH, which is responsible for normal follicular growth, gonadal steroid production, spermatogenesis and follicular maturation.

  • Abdominal cramps
  • Abdominal pain
  • Headache
  • Ovarian hyperstimulation syndrome
  • Nausea
  • Vaginal hemorrhage
  • Ovarian cysts
  • Pelvic pain
  • Abdominal distension
  • Pain
  • URI
  • Hot flashes
  • Injection site reaction
  • UTI
  • Hypersensitivity to components
  • Pregnancy
  • Primary ovarian failure
  • Uncontrolled thyroid disease
  • Uncontrolled adrenal dysfunction
  • Uncontrolled pituitary dysfunction
  • Breast cancer
  • Ovarian cancer
  • Uterine cancer
  • Hypothalamic tumor
  • Pituitary tumor
  • Organic intracranial lesion
  • Abnormal uterine bleeding
  • Non-PCOS-associated ovarian cyst

None remarkable

                          Drug Status

Availability Prescription only
Pregnancy Category X
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Endogen HP 75 IU Injection 2mL Sanzyme Ltd C/O Surgilinks Avacare Kenya